Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pharmaust Limited ( (AU:NUZ) ) just unveiled an update.
Neurizon Therapeutics Limited has announced that its next Annual General Meeting (AGM) will be held on September 30, 2025. The meeting will include an election of directors, with nominations closing on August 12, 2025. This announcement is significant for stakeholders as it outlines the timeline for director nominations and elections, which are crucial for the company’s governance and strategic direction.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company is advancing its lead drug candidate, NUZ-001, for the treatment of ALS, the most common form of motor neurone disease. Neurizon aims to accelerate access to effective ALS treatments and explore broader neurodegenerative applications through international collaborations and rigorous clinical programs.
Average Trading Volume: 348,378
Technical Sentiment Signal: Buy
Current Market Cap: A$83.69M
Find detailed analytics on NUZ stock on TipRanks’ Stock Analysis page.